Résumé
A better identification of patients who are more likely to benefit from vascular endothelial growth factor–targeted therapy is warranted in metastatic renal cell carcinoma. High VFA could be a predictive biomarker from shorter survival in patients given first-line antiangiogenic agents for metastatic renal cell carcinoma.